about
Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus ErythematosusAltered expression of the tetraspanin CD81 on B and T lymphocytes during HIV-1 infectionAlterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancyRole of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodiesAnti-inflammatory and immunosuppressive drugs and reproductionType 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infectionInternational consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathyThrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factorChallenges and treatment options for rheumatoid arthritis during pregnancy.The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis.Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.Endothelium activation in the anti-phospholipid syndrome.Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis.Features associated with epilepsy in the antiphospholipid syndrome.Role of infectious agents in systemic rheumatic diseases.The geoepidemiology of the antiphospholipid antibody syndrome.Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients.Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.Anti-mitochondrial type M5 and anti-cardiolipin antibodies in autoimmune disorders: studies on their association and cross-reactivity.What is the pathogenetic role of antiphospholipid antibodies?Anti-mitochondrial M5 type antibody represents one of the serological markers for anti-phospholipid syndrome distinct from anti-cardiolipin and anti-beta2-glycoprotein I antibodies.Anti beta2-glycoprotein I antibodies: clinical significance.Differences in serum and synovial CD4+ T cells and cytokine profiles to stratify patients with inflammatory osteoarthritis and rheumatoid arthritisIL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease.EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndromeIntracerebral haemorrhage, a possible presentation in Churg-Strauss syndrome: case report and review of the literature.Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.Human T-lymphotropic virus type 2 (HTLV-2) provirus in circulating cells of the monocyte/macrophage lineage in patients dually infected with human immunodeficiency virus type 1 and HTLV-2 and having predominantly sensory polyneuropathyLimited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signatureNeonatal lupus syndromes.QT interval prolongation in asymptomatic anti-SSA/Ro-positive infants without congenital heart block.The story of the murine antiendothelial monoclonal antibody BGM. From patients' bedside to laboratory bench and from animal models to patients.Prevention and treatment of lethal murine endotoxemia by the novel immunomodulatory agent MFP-14.Overview on anticardiolipin ELISA standardization.Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome.Autoimmune or auto-inflammatory syndrome induced by adjuvants (ASIA): old truths and a new syndrome?High IL-17E and low IL-17C dermal expression identifies a fibrosis-specific motif common to morphea and systemic sclerosis.Peripheral blood mononuclear cell beta-endorphin concentration is decreased in chronic fatigue syndrome and fibromyalgia but not in depression: preliminary report.
P50
Q26766428-77FFEB18-A8F3-47D3-B1BC-FE1041E8689FQ27478138-E8474FA4-E330-423F-875B-A38F900D739BQ28168298-5EBE2F94-BF70-46A3-8716-38D683C30D6EQ28203584-AB1819E0-6885-4878-9D8B-85A06F9CC384Q28218219-38B849C8-3F0E-4E0A-93DC-5DCD6A5E93D0Q28291387-910B2C8B-3CDB-42E3-8AD5-C2BEC3B1F5BDQ28292418-A154ECD8-44BE-4A84-AD94-C1D5CBBC40F6Q28361324-6053889F-A27E-475E-A501-24A0AFAEA771Q28565242-A0735373-5FC8-485D-BB9C-6FFF8A8E9E3EQ30249730-71AFCCA2-7D03-4C68-81FC-7DBBCD65DD20Q30713980-2C4899EE-E007-4984-899C-B73A1325DDDAQ31021097-147BEFF2-9F9A-4A56-AB80-42F1C597C52CQ33341941-F6365321-33A2-4925-8C53-3D4D75D253E5Q33356831-B4FAD8C3-21E9-4732-B3F3-48D0AEF70B55Q33358476-8C96D76F-508D-4A50-BC56-AF0C312660F6Q33361525-B3D1289A-6739-4D18-82C8-F1E85E92D061Q33380043-BFF602F8-6CE9-4AAE-A3D0-05DCF5A3EB9DQ33387143-FB9281C3-D422-483C-94A6-C37F0F0F15E5Q33394453-9F77D636-7516-424B-A608-F6CC49F83B2EQ33412915-599C5C00-729F-4B38-864F-AB8EA1A50CAEQ33454479-2E103C96-B950-4BD9-B27D-D488A9E8C5E8Q33491146-FCC0AC67-8A0E-421A-999C-8C7F68CF0D6DQ33502295-12A3337A-C33F-4A30-806F-E766B1E1098FQ33504228-435FB02D-E2E8-4F08-B238-4D45492865F5Q33706318-DA677143-E3E3-4A04-99EB-3D6CB85B58F8Q33715791-7EC07C36-B3D9-4D69-8BD2-E235DC4C9BCFQ33731711-9BB856D3-BD63-46A3-9BF6-506FDA5D05FCQ33752797-8F542251-95E5-4644-B11E-AB16BFCFE21DQ33766670-B9AE4CDF-5357-4576-AD73-6708A6D26A7DQ33784108-B0E94006-D401-44CF-95ED-BC6B1D55F410Q33868785-8FE248D2-3A14-4C00-B614-37AB908C254DQ33895932-6376D211-3E38-4690-AA1A-C2D171748BF6Q33922169-9ED2F9B0-2363-4670-BFC5-E6B727104B0AQ33976555-8A64EE26-31AC-454F-BDDE-C4986C7F6BCFQ33982156-E396C798-1625-4C65-A6DE-3A4A9599A80BQ34021272-EF9C5725-8694-4EDA-8F03-A9497D968625Q34021310-29873D48-A493-417E-B795-8360739DAE7AQ34024573-F8D20FFB-3D87-48A6-B58F-B551CD163AD1Q34066564-A93E00AC-ED55-451B-A7D8-A6031B2B515EQ34140278-C05F3B19-4F7C-4169-8B15-996A5F4D26D2
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Pier Luigi Meroni
@ast
Pier Luigi Meroni
@da
Pier Luigi Meroni
@de
Pier Luigi Meroni
@en
Pier Luigi Meroni
@es
Pier Luigi Meroni
@fr
Pier Luigi Meroni
@nb
Pier Luigi Meroni
@nl
Pier Luigi Meroni
@nn
Pier Luigi Meroni
@sl
type
label
Pier Luigi Meroni
@ast
Pier Luigi Meroni
@da
Pier Luigi Meroni
@de
Pier Luigi Meroni
@en
Pier Luigi Meroni
@es
Pier Luigi Meroni
@fr
Pier Luigi Meroni
@nb
Pier Luigi Meroni
@nl
Pier Luigi Meroni
@nn
Pier Luigi Meroni
@sl
prefLabel
Pier Luigi Meroni
@ast
Pier Luigi Meroni
@da
Pier Luigi Meroni
@de
Pier Luigi Meroni
@en
Pier Luigi Meroni
@es
Pier Luigi Meroni
@fr
Pier Luigi Meroni
@nb
Pier Luigi Meroni
@nl
Pier Luigi Meroni
@nn
Pier Luigi Meroni
@sl
P214
P244
P1053
K-8473-2016
P106
P1153
35376419500
P21
P213
0000 0000 3761 7742
P214
P244
nb2001025779
P31
P3829
P496
0000-0002-3394-1451
P735
P7859
lccn-nb2001025779